ENDOCANNABINOID SYSTEM AND NEUROCARDIOLOGY: IMPACTS ON AUTONOMIC REGULATION AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH NEUROLOGICAL DISORDERS
DOI:
https://doi.org/10.36557/2009-3578.2025v11n2p3664-3678Palabras clave:
Endocannabinoid system; Autonomic regulation; Neurological disorders.Resumen
This study aimed to examine the influence of the endocannabinoid system (ECS) on autonomic regulation and cardiovascular outcomes in patients with neurological disorders. An Integrative Literature Review (ILR) was conducted across SciELO, LILACS, PubMed, and ScienceDirect databases, covering the period from 2018 to 2025, and including original articles published in Portuguese and English. The synthesis of findings highlighted the distinct roles of CB₁ and CB₂ receptors, whose effects ranged from protective actions to potential risks for autonomic and cardiovascular stability. The CB₂ receptor demonstrated a relevant role in reducing vascular inflammation and protecting against ischemic events, whereas CB₁ was associated both with nitric oxide–mediated hypotensive effects and with episodes of tachycardia and autonomic instability. In the field of neurocardiology, the reviewed studies suggest that the ECS modulates norepinephrine release from sympathetic fibers, directly influencing hemodynamic control. Recent clinical trials reported that cannabidiol (CBD) may lower blood pressure and improve autonomic variability parameters, particularly in hypertensive patients or under stress conditions. However, these findings remain limited by small sample sizes, methodological heterogeneity, and the scarcity of large-scale randomized clinical trials. It is concluded that the ECS represents a promising biological axis for understanding the interface between neurological diseases, autonomic dysfunction, and cardiovascular risk. Nonetheless, further targeted investigations are required to confirm the efficacy and safety of cannabinoid use in specific clinical contexts. The integration of neuroscience, cardiology, and pharmacology may pave the way for innovative therapeutic approaches aimed at preventing cardiovascular complications in neurological patients.
Descargas
Citas
BATINIC, A. et al. Trial of a novel oral cannabinoid formulation in patients with hypertension: a double-blind, placebo-controlled pharmacogenetic study. Pharmaceuticals (Basel), v. 16, n. 5, p. 645, 2023. DOI: 10.3390/ph16050645. Available at: https://doi.org/10.3390/ph16050645. Accessed on: Sept. 4, 2025.
CHEN, F. Y. et al. 19 patients report seizure freedom with medical cannabis oil treatment for drug-resistant epilepsy: a case series. Frontiers in Neuroscience, v. 19, 2025. DOI: 10.3389/fnins.2025.1570531. Available at: https://doi.org/10.3389/fnins.2025.1570531. Accessed on: Sept. 5, 2025.
DRAGUN, T. et al. The influence of oral cannabidiol on 24-h ambulatory blood pressure and arterial stiffness in untreated hypertension: a double-blind, placebo-controlled, cross-over pilot study. Advances in Therapy, v. 40, n. 8, p. 3495-3511, 2023. DOI: 10.1007/s12325-023-02560-8. Available at: https://doi.org/10.1007/s12325-023-02560-8. Accessed on: Sept. 5, 2025.
FILIPPINI, G. et al. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane Database of Systematic Reviews, v. 2022, n. 5, Art. No.: CD013444, 2022. DOI: 10.1002/14651858.CD013444.pub2. Available at: https://doi.org/10.1002/14651858.CD013444.pub2. Accessed on: Sept. 5, 2025.
FONSECA, C. D. F. et al. Cannabinoids and the endocannabinoid system in the regulation of cytochrome P450 metabolic activity – a review. Frontiers in Pharmacology, v. 16, June 5, 2025. Drug Metabolism and Transport section. DOI: 10.3389/fphar.2025.1599012. Available at: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1599012/. Accessed on: Sept. 2, 2025.
FULMER, M. L.; THEWKE, D. P. The endocannabinoid system and heart disease: the role of cannabinoid receptor type 2. Cardiovascular & Hematological Disorders Drug Targets, v. 18, n. 1, p. 34-51, 2018. DOI: 10.2174/1871529X18666180206161457. Available at: https://doi.org/10.2174/1871529X18666180206161457. Accessed on: Sept. 4, 2025.
GANONG, L. H. Integrative reviews of nursing research. Research Nursing Health, v. 10, n. 1, p. 01-10, 1987. Available at: https://pubmed.ncbi.nlm.nih.gov/3644366/. Accessed on: Sept. 4, 2025.
KRZYŻEWSKA, A. et al. Comprehensive mini-review: therapeutic potential of cannabigerol – focus on the cardiovascular system. Frontiers in Pharmacology, v. 16, Mar. 25, 2025. Experimental Pharmacology and Drug Discovery section. DOI: 10.3389/fphar.2025.1561385. Available at: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1561385/full?. Accessed on: Sept. 1, 2025.
LOCKWOOD, C. et al. Systematic reviews of qualitative evidence. In: AROMATARIS, E.; MUNN, Z. (Editors). JBI Manual for Evidence Synthesis. JBI, 2020. Available at: https://jbi-global-wiki.refined.site/space/MANUAL/355860482. Accessed on: Sept. 4, 2025.
LOCKWOOD, C.; MUNN, Z.; PORRITT, K. Qualitative research synthesis: methodological guidance for systematic reviewers utilizing meta-aggregation. International Journal of Evidence-based Healthcare, v. 13, n. 3, p. 179-187, 2015. Available at: https://pubmed.ncbi.nlm.nih.gov/26262565/. Accessed on: Sept. 4, 2025.
LONGORIA, V. et al. Neurological benefits, clinical challenges, and neuropathologic promise of medical marijuana: a systematic review of cannabinoid effects in multiple sclerosis and experimental models of demyelination. Biomedicines, v. 10, n. 3, p. 539, 2022. DOI: 10.3390/biomedicines10030539. Available at: https://doi.org/10.3390/biomedicines10030539. Accessed on: Sept. 5, 2025.
LOWE, H. et al. The endocannabinoid system: a potential target for the treatment of various diseases. International Journal of Molecular Sciences, v. 22, n. 17, p. 9472, 2021. DOI: 10.3390/ijms22179472. Available at: https://doi.org/10.3390/ijms22179472. Accessed on: Sept. 5, 2025.
MATEI, D. et al. The endocannabinoid system and physical exercise. International Journal of Molecular Sciences, v. 24, n. 3, p. 1989, 2023. DOI: 10.3390/ijms24031989. Available at: https://doi.org/10.3390/ijms24031989. Accessed on: Sept. 4, 2025.
MOHER, D. et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med., v. 6, n. 7, p. e1000097, 2009. Available at: https://pubmed.ncbi.nlm.nih.gov/19621072/. Accessed on: Sept. 4, 2025.
O'SULLIVAN, S. E. Endocannabinoids and the cardiovascular system in health and disease. Handbook of Experimental Pharmacology, v. 231, p. 393-422, 2015. DOI: 10.1007/978-3-319-20825-1_14. Available at: https://doi.org/10.1007/978-3-319-20825-1_14. Accessed on: Sept. 4, 2025.
PABON, E. et al. Acute effects of oral delta-9-tetrahydrocannabinol (THC) on autonomic cardiac activity and their relation to subjective and anxiogenic effects. Psychophysiology, v. 59, n. 2, e13955, 2022. DOI: 10.1111/psyp.13955. Available at: https://doi.org/10.1111/psyp.13955. Accessed on: Sept. 6, 2025.
PAULRAJ, S. et al. Arrhythmias and cannabis use: a comprehensive overview. Heart Rhythm O2, v. 6, n. 1, p. 78-85, 2024. DOI: 10.1016/j.hroo.2024.10.020. Available at: https://doi.org/10.1016/j.hroo.2024.10.020. Accessed on: Sept. 5, 2025.
SAJDEYA, R. et al. Clinical considerations for cannabis use and cardiovascular health. Medical Cannabis and Cannabinoids, v. 5, n. 1, p. 120-127, 2022. DOI: 10.1159/000526731. Available at: https://doi.org/10.1159/000526731. Accessed on: Sept. 4, 2025.
SINGH, A. et al. Cardiovascular complications of marijuana and related substances: a review. Cardiology and Therapy, v. 7, n. 1, p. 45-59, 2018. DOI: 10.1007/s40119-017-0102-x. Available at: https://doi.org/10.1007/s40119-017-0102-x. Accessed on: Sept. 6, 2025.
ŠOŠA, I. A meta-narrative review of channelopathies and cannabis: mechanistic, epidemiologic, and forensic insights into arrhythmia and sudden cardiac death. International Journal of Molecular Sciences, v. 26, n. 17, p. 8635, 2025. DOI: 10.3390/ijms26178635. Available at: https://doi.org/10.3390/ijms26178635. Accessed on: Sept. 4, 2025.
SOUZA, M. T.; SILVA, M. D.; CARVALHO, R. Integrative review: what is it? How to do it? Einstein, v. 8, n. 1, p. 102-106, 2010. Available at: https://www.scielo.br/j/eins/a/ZQTBkVJZqcWrTT34cXLjtBx/?format=pdf&lang=pt. Accessed on: Sept. 5, 2025.
STERN, C.; JORDAN, Z.; MCARTHUR, A. Developing the review question and inclusion criteria. The American Journal of Nursing, v. 14, n. 4, p. 53-56, 2014. Available at: https://pubmed.ncbi.nlm.nih.gov/24681476/. Accessed on: Sept. 4, 2025.
WATANABE, A. H.; CHAIYAKUNAPRUK, N. et al. A systematic review and meta-analysis of randomized controlled trials of cardiovascular toxicity of medical cannabinoids. Journal of the American Pharmacists Association (2003), v. 61, n. 5, p. e1-e13, 2021. DOI: 10.1016/j.japh.2021.03.013. Available at: https://doi.org/10.1016/j.japh.2021.03.013. Accessed on: Sept. 6, 2025.
ZERTAL, A. et al. Efficacy of cannabinoids compared to the current standard treatments on symptom relief in persons with multiple sclerosis (CANSEP trial): study protocol for a randomized clinical trial. Frontiers in Neurology, v. 15, 2024. DOI: 10.3389/fneur.2024.1440678. Available at: https://doi.org/10.3389/fneur.2024.1440678. Accessed on: Sept. 5, 2025.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2025 Arthur Junqueira Ferreira Santos, Loren Ferrarezi, Rodolfo de Oliveira Medeiros, Guilherme de Lúcio Consalter, Camila Menon Oliveros, Sofia Leoncini de Almeida, Sophia Evaristo Coércio, Renato Augusto Paro Lima, Gabriel Baraldi Labegalini, João Victor Cardoso Casarin
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Você tem o direito de:
- Compartilhar — copiar e redistribuir o material em qualquer suporte ou formato para qualquer fim, mesmo que comercial.
- Adaptar — remixar, transformar, e criar a partir do material para qualquer fim, mesmo que comercial.
De acordo com os termos seguintes:
- Atribuição — Você deve dar o crédito apropriado , prover um link para a licença e indicar se mudanças foram feitas . Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
- Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.
